Table 2.

Outcomes 24 weeks after immediate ART among patients with an acute OI in South Africa

	Patients (N =382) n (%) or median [IQR]
Timing of ART initiation
Days from admission with OI to ART initiation*	14 [11–18]
Days from admission with OI to ART by category
0–7	15 (4)
8–14	181 (47)
15–21	105 (26)
>21	62 (16)
Total in-patient days in in-patient care
Days from hospital admission to discharge home	19 [15–26]
ART regimen initiated
d4T+3TC + EFV	366 (95)
d4T+3TC + NVP	6 (2)
AZT+3TC + EFV	6 (2)
Other	4 (1)
24-week virologic outcomes
ITT viral suppression <400 cells/ml†	206 (57)
AT viral suppression <400 cells/ml‡	206 (93)
24-week immunologic outcomes
CD4 count improvement, cells/mm3§	100 [48–188]
24-week mortality
Overall mortality	97 (25)
Mortality prior to discharge in the step-down facility	20/97
Mortality after discharge	77/97
Among patients who died, days to death	33 [9–95]
24-week program outcomes
Loss to follow-up	19 (5)
Changed service provider	19 (5)

^*Date of ART initiation unknown for a proportion (n = 19) of patients.

^†For ITT analysis, patients who died (n = 97), were lost to follow-up (n = 19) or were in care but missing 24-week viral load data were considered unsuppressed (n = 60). Only those who transferred care (n = 19) were excluded.

^‡For the AT analysis, patients who died (n = 97), were lost to follow-up (n = 19), or who were in care but were missing 24-week data (n = 60) or transferred care (n = 19) were excluded.

^§Excludes patients who died, were lost to follow-up, were missing baseline or 24-week CD4 cell count (n = 23), or who transferred care.

ART = antiretroviral therapy; OI = opportunistic infection; IQR = inter quartile range; d4T = stavudine; 3TC = lamivudine; EFV = efavirenz; NVP = nevirapine; AZT = zidovudine; ITT = intent-to-treat; AT = as-treated.